

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.

Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30-09-2024

			Quarter ended	T	the second s	millions except	Year ended
S.No.	Particulars			30-09-2023	Half year ended 30-09-2024 30-09-2023		31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from operations	13,711	13,626	10,314	27,337	21,719	39,988
2	Other income	638	481	294	1,119	491	1,281
3	Total income (1+2)	14,349	14,107	10,608	28,456	22,210	41,269
4	Expenses						
	Cost of materials consumed	1,432	1,513	1,665	2,945	3,027	5,225
	Purchases of stock-in-trade	537	325	410	862	836	1,514
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(193)	(36)	83	(229)	255	427
	Employee benefits expense	1,515	1,420	1,224	2,935	2,606	5,250
	Finance costs	41	52	42	93	84	192
	Depreciation and amortisation expense	458	441	436	899	871	1,868
	Other expenses	2,377	2,356	2,352	4,733	5,135	10,058
	Total expenses	6,167	6,071	6,212	12,238	12,814	24,534
5	Profit before tax for the period/ year (3-4)	8,182	8,036	4,396	16,218	9,396	16,735
6	Tax expense						
	(i) Current tax	1,541	1,436	819	2,977	1,740	3,165
	(ii) Deferred tax	(124)	(85)	(113)	(209)	(237)	(313
	Total tax expense	1,417	1,351	706	2,768	1,503	2,852
7	Profit for the period/ year (5-6)	6,765	6,685	3,690	13,450	7,893	13,883
8	Other comprehensive income/ (loss) (net of tax)						
	(i). Items that will not be reclassified to profit or loss:						
	Remeasurement of defined benefit liability/(asset)	-	-	-	-		(20
	Tax on remeasurement of defined benefit liability/(asset)	-	-	× .	-		7
	Fair value changes of Equity investments through OCI	50	26	25	76	76	97
	Tax impact in Fair value changes on Equity investments through OCI	(7)	(4)	(3)	(11)	(7)	(8
		43	22	22	65	69	76
	(ii). Items that will be reclassified to profit or loss:	140	(400)	(70)	147)	26	70
	Exchange differences on translating financial statements of foreign operations	149	(166)	(70)	(17)	26	73
		149	(166)	(70)	(17)	26	73
	Other comprehensive income/ (loss) for the period/ year, net of tax	192	(144)	(48)	48	95	149
9	Total comprehensive income for the period/ year (7+8)	6,957	6,541	3,642	13,498	7,988	14,032
10	Profit for the period/year attributable to:						
10	Owners of the Company	6,773	6,685	3,690	13,458	7,893	13,883
	Non-controlling interests	(8)	-	-	(8)	-	-
11	Other comprehensive income for the period/ year attributable to:						
	Owners of the Company	192	(144)	(48)	48	95	149
	Non-controlling interests	-	(144)	(40)	-	-	-
	<b>3</b>						
12	Total comprehensive income for the period/ year attributable to:				10 500	7.000	11000
	Owners of the Company Non-controlling interests	6,965	6,541	3,642	13,506	7,988	14,032
42	Paid-up equity share capital (Face value of ₹2 each)	(8) <b>358</b>	- 358	358	(8) <b>358</b>	358	358
13		308	338	300	330	530	58,173
14	Other equity						56,173
15	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)						
	Basic (in ₹)	37.81	37.32	20.60	75.14	43.88	77.34
	Diluted (in ₹)	37.81	37.32	20.60	75.14	43.88	77.34

See accompanying notes to the unaudited consolidated financial results.





	As at 30-09-2024 (Unaudited)	(₹ in million As at 31-03-2024 (Audited)
Assets	(endudited)	(ridditod)
1) Non-current assets		
(a) Property, plant and equipment	23,037	22,9
(b) Capital work-in-progress	2,345	1,3
(c) Goodwill	562	5
(d) Other intangible assets	1,814	1,3
(e) Financial assets	1,014	1,3
	1 000	
(i) Investments	1,686	9
(ii) Other financial assets	1,993	4
(f) Deferred tax assets, net	385	1
(g) Non-current tax assets, net	26	2
(h) Other non-current assets	584	6
Total non-current assets	32,432	28,8
2) Current assets		
(a) Inventories	7,746	7,0
(b) Financial assets		
(i) Investments	4,744	4,4
(ii) Trade receivables	14,357	11,8
(iii) Cash and cash equivalents	1,046	7
(iv) Bank balances other than (iii) above	14,575	8.8
(v) Loans	101	
(v) Other financial assets	4,269	4,5
(c) Other current assets	3,177	2,7
Total current assets	50,015	40,2
Total assets	82,447	69,0
EQUITY AND LIABILITIES 1) Equity (a) Equity share capital (b) Other equity	358 71,141	3 58,1
Equity attributable to owners of the Company	71,499	58,5
Equity attributable to entitle of the company	11,400	
(c) Non-controlling interest	69	
	2	58,5
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> </ul> </li> </ul>	69	58,5
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> </ul> </li> </ul>	69 <b>71,568</b> 51	
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> </ul> </li> </ul>	69 <b>71,568</b> 51 44	
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> </ul> </li> </ul>	69 <b>71,568</b> 51 44 695	7
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities</li> </ul>	69 71,568 51 44 695 2	7
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities</li> <li>(B) Current liabilities</li> </ul>	69 71,568 51 44 695 2	7
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(B) Current liabilities</li> <li>(a) Financial liabilities</li> </ul> </li> </ul>	69 71,568 51 44 695 2 <b>792</b>	7
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Current liabilities</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> </ul>	69 71,568 51 44 695 2 792 2,010	7 <b>8</b> 3,6
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities</li> </ul> </li> </ul>	69 71,568 51 44 695 2 <b>792</b>	7 <b>8</b> 3,6
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(B) Current liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables</li> </ul> </li> </ul>	69 71,568 51 44 695 2 <b>792</b> 2,010 23	7 <b>8</b> 3,6
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Current liabilities</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Jease liabilities</li> <li>(c) Jease liabilities</li> </ul> </li> </ul>	69 71,568 51 44 695 2 792 792 2,010 23 96	7 <b>8</b> 3,6
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(b) Financial liabilities</li> <li>(c) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Journe payables</li> <li>Total outstanding dues of micro enterprises and small enterprises; and -Total outstanding dues of creditors other than micro enterprises and</li> </ul> </li> </ul>	69 71,568 51 44 695 2 <b>792</b> 2,010 23	7 <b>8</b> 3,6
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables</li> <li>Total outstanding dues of micro enterprises and small enterprises; and -Total outstanding dues of creditors other than micro enterprises and small enterprises</li> </ul> </li> </ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048	7 <b>8</b> 3,6 2,3
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(b) Financial liabilities</li> <li>(c) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Journe payables</li> <li>Total outstanding dues of micro enterprises and small enterprises; and -Total outstanding dues of creditors other than micro enterprises and</li> </ul> </li> </ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048 1,052	7 <b>8</b> 3,6 2,3 1,0
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities</li> <li>(c) Deferred tax liabilities</li> <li>(d) Financial liabilities</li> <li>(e) Provisions</li> <li>(f) Deferred tax liabilities</li> <li>(g) Current liabilities <ul> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables</li> <li>Total outstanding dues of micro enterprises and small enterprises; and -Total outstanding dues of creditors other than micro enterprises and small enterprises</li> </ul> </li> </ul></li></ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048	7 <b>8</b> 3,6 2,3 1,0 1,3
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(B) Current liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables <ul> <li>Total outstanding dues of micro enterprises and small enterprises; and</li> <li>Total outstanding dues of creditors other than micro enterprises and small enterprises</li> <li>(iii) Other financial liabilities</li> </ul> </li> </ul></li></ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048 1,052	7 <b>8</b> 3,6 2,3 1,0
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Current liabilities</li> <li>(a) Financial liabilities</li> <li>(b) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables <ul> <li>Total outstanding dues of micro enterprises and small enterprises; and</li> <li>Total outstanding dues of creditors other than micro enterprises and small enterprises</li> <li>(iii) Other financial liabilities</li> <li>(b) Other current liabilities</li> <li>(c) Provisions</li> </ul> </li> </ul></li></ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048 1,052 1,785 870	7 <b>8</b> 3,6 2,3 1,0 1,3 1,0
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ib) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(B) Current liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables <ul> <li>Total outstanding dues of micro enterprises and small enterprises; and</li> <li>Total outstanding dues of creditors other than micro enterprises and small enterprises</li> <li>(iii) Other financial liabilities</li> </ul> </li> </ul></li></ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048 1,052 1,785	7 <b>8</b> 3,6 2,3 1,0 1,3 1,0 3
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ia) Lease liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Current liabilities</li> <li>(c) Deferred tax liabilities</li> </ul> </li> <li>(b) Current liabilities <ul> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(a) Financial liabilities</li> <li>(b) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Borrowings</li> <li>(c) Lease liabilities</li> <li>(c) Total outstanding dues of micro enterprises and small enterprises; and -Total outstanding dues of creditors other than micro enterprises and small enterprises</li> <li>(ii) Other financial liabilities</li> <li>(b) Other current liabilities</li> <li>(c) Provisions</li> <li>(d) Current tax liabilities (net)</li> </ul> </li> <li>Total current liabilities (net)</li> </ul>	69 71,568 51 44 695 2 792 2,010 23 96 3,048 1,052 1,785 870 1,203 10,087	7 8 3,6 2,3 1,0 1,3 1,0 3 1,0 3 9,7
<ul> <li>(c) Non-controlling interest Total equity</li> <li>2) Liabilities <ul> <li>(A) Non-current liabilities</li> <li>(a) Financial liabilities</li> <li>(ii) Other financial liabilities</li> <li>(b) Provisions</li> <li>(c) Deferred tax liabilities (net)</li> </ul> </li> <li>Total non-current liabilities <ul> <li>(B) Current liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(i) Borrowings</li> <li>(ia) Lease liabilities</li> <li>(ii) Trade payables <ul> <li>Total outstanding dues of micro enterprises and small enterprises; and</li> <li>Total outstanding dues of creditors other than micro enterprises and small enterprises</li> <li>(ii) Other financial liabilities</li> <li>(b) Other current liabilities</li> <li>(c) Provisions</li> <li>(d) Current tax liabilities</li> </ul> </li> </ul></li></ul>	69 71,568 51 44 695 2 792 792 2,010 23 96 3,048 1,052 1,785 870 1,203	7 8 3,6 2,3 1,0 1,3

anan

5

4



Consolidated Statement of Cash Flows:	Half year	<i>(₹ in millio</i> rended
	30-09-2024 Unaudited	30-09-2023 Unaudited
Cash flows from operating activities		
Profit before tax for the period	16,218	9.3
Adjustments for		
Depreciation and amortisation expense	899	
inance costs	93	
nterest income	(783)	(3
rovision for impairment of receivables and advances, net	-	
ad debts written off		
let Loss/ (gain) on sale of property, plant and equipment and intangible assets	4	
let gain on sale of investments	(5)	
lividend income on equity investment at fair value through other comprehensive income	(2)	
change in fair value of financial assets measured at fair value through profit and loss	(104)	
Inrealised foreign exchange gain, net	(17)	
perating profit before working capital changes	16,303	10,
hanges in working capital:		
ncrease)/ decrease in inventories	(741)	
ncrease in trade receivables	(2,449)	(2,7
ncrease)/ decrease in other financial assets	(3)	
ncrease in other assets	(415)	(6
ncrease in trade payables	789	1,
Decrease)/ increase in provisions	(173)	.,
Decrease)/ increase in other financial liabilities	(29)	
Decrease in other liabilities	(57)	(6
Cash generated from operating activities	13,225	7,
ncome-taxes paid, net of refund	(1,855)	(1,*
let cash generated from operating activities (A)	11,370	6,
the own generated norm operating derivities (A)	11,370	0,.
Cash flows from investing activities		
-	(1.000)	14
Purchase of property, plant and equipment	(1,690)	(1,4
Proceeds from sale of property, plant and equipment	2	
Advance for sale of property, plant and equipment	501	
Acquisition of intangible assets	(711)	(*
Proceeds from sale of intangible assets	201	
Repayment of loans by others	(11)	
Proceeds from sale of investments	1,768	1,0
Purchase of investments		
	(2,560)	3)
Deposits with banks	(10,982)	(5,2
Redemption of bank deposits	5,231	3,
nterest received	733	
Dividend received	2	
Redemption of deposits other than with banks	1,626	2,
Deposits other than with banks	(2,927)	(3,0
let cash used in investing activities (B)		
et cash used in investing activities (D)	(8,817)	(3,4
Cash flows from financing activities		
Proceeds from issue of shares by subsidiary	77	
Payment on buy-back of shares, including transaction costs and taxes on buy-back	-	(2,5
let proceeds/ (repayment of) from short-term borrowings (refer note below)	(1,624)	
Dividends paid	(538)	(1,2
Finance cost paid	(91)	( ),
Principal and interest payment of lease liabilities (refer note (c) below)	(15)	10
let cash used in financing activities (C)	(2,191)	(3,1
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	362	(2
Cash and cash equivalents as at the beginning of the period	704	1,
Effect of currency translation adjustment	(20)	
Cash and cash equivalents as at the end of the period	1,046	1,0
	1,040	1,0
lote: Movement in borrowings and lease liabilities in accordance with Ind AS 7:	1	
Current borrowings		- LOC
Opening balance	3,632	1
Proceeds from/ (repayment of) borrowings, net	(1,624)	
Non-cash items (foreign exchange changes)	2	
	2 0 1 0	2,
0.1.90	2,010	2
ease liabilities		
Opening balance	80	
Cash flow changes	(15)	
Non-cash changes	9	
	74	
	(4)	

1



Segme	ent reporting:	
S No.	Particulars	-

(₹ in millions except share data)

		Quarter ended			Half yea	r ended	Year ended	
S.No.	Particulars	30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Segment revenue							
	a. Pharmaceuticals	13,562	13,470	9,796	27,032	20,714	38,905	
	b. Agro chemicals	149	156	518	305	1,005	1,083	
	b. Agro chemicais	13,711	13,626	10,314	27,337	21,719	39,988	
	Add: Unallocated	13,711	13,020	10,514	21,331	21,719	39,900	
	Total revenue from operations	13,711	13,626	10,314	27,337	21,719	39,988	
2	Segment results							
-	a. Pharmaceuticals	8,461	8,286	4,397	16,747	9,396	17,523	
	b. Agro chemicals	(238)	(198)	41	(436)	84	(596)	
	Total segment result	8,223	8,088	4,438	16,311	9,480	16,927	
	Less:							
	a. Finance costs	(41)	(52)	(42)	(93)	(84)	(192)	
	b. Net unallocated (income)/expenditure	-	-	-	-	-	-	
	Total profit before tax	8,182	8,036	4,396	16,218	9,396	16,735	
3	Segment assets							
	a. Pharmaceuticals	51,295	48,882	53,731	51,295	53,731	45,650	
	b. Agro chemicals	4,057	4,165	4,439	4,057	4,439	4,238	
	Total segment assets	55,352	53,047	58,170	55,352	58,170	49,888	
	Add:							
	a. Unallocated	27,095	20,929	4,370	27,095	4,370	19,175	
	Total assets	82,447	73,976	62,540	82,447	62,540	69,063	
4	Segment liabilities							
	a. Pharmaceuticals	7,072	6,154	6,369	7,072	6,369	5,807	
	b. Agro chemicals	463	461	129	463	129	588	
	Total segment liabilities	7,535	6,615	6,498	7,535	6,498	6,395	
	Add:							
	a. Unallocated	3,344	2,290	3,107	3,344	3,107	4,137	
	Total liabilities	10,879	8,905	9,605	10,879	9,605	10,532	

Continued..

0

Z

was

=1



### Notes to the unaudited consolidated financial results:

- The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited consolidated financial results for the quarter and half year ended 30-09-2024 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 12-11-2024.
- 3) The unaudited consolidated financial results of the Group for the quarter and half year ended 30-09-2024, have been reviewed by the statutory auditors and they have issued an unmodified reviewed report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The unaudited consolidated financial results for the quarter and half year ended 30-09-2024 includes financial results of the following subsidiaries/step-down subsidiaries:

Sr. No	Name of the Entity
1	NATCO Pharma Inc., United States of America
2	NATCO Pharma USA LLC (Formerly known as Dash Pharmaceuticals LLC), United States of America
3	Time Cap Overseas Limited, Mauritius
4	NatcoFarma do Brasil Ltda, Brazil (subsidiary of Time Cap Overseas Limited)
5	NATCO Pharma (Canada) Inc., Canada
6	NATCO Pharma Asia Pte. Ltd., Singapore
7	NATCO Pharma Australia PTY Ltd., Australia
8	NATCO Lifesciences Philippines Inc., Philippines
9	NATCO Pharma UK Limited, United Kingdom incorporated on 04-09-2023
10	PT. NATCO Lotus Farma, Indonesia incorporated on 28-08-2023
11	NATCO Pharma Colombia S.A.S, Colombia incorporated on 15-08-2023

5) The unaudited standalone financial results, for the quarter and half year ended 30-09-2024 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of unaudited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

					(	₹ in millions)
	0	Quarter ende	d	Half yea	Year ended	
Particulars	30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
l'articulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income	13,440	12,767	9,552	26,207	20,181	36,736
Profit before tax	7,969	7,580	4,240	15,549	8,992	15,553
Net profit for the period/ year	6,611	6,363	3,602	12,974	7,655	13,066
Total comprehensive income for the period/ year	6,654	6,385	3,624	13,039	7,724	13,142

6) The Board of Directors at their meeting held on 12-11-2024 have approved an interim dividend of ₹ 1.5/- per equity share of ₹ 2 each for the quarter ended 30-09-2024 and at their meeting held on 12-08-2024 had approved interim dividend of ₹ 3/- per equity share of ₹ 2 each for the quarter ended 30-06-2024.

By order of the Board For NATCO Pharma Limited

V C Nannapanen Chairman & Managing Director (DIN: 00183315)

Place: Hyderabad Date: 12 November 2024

Salarpuria Knowledge City, Orwell B Wing, 6th Floor, Unit-3, Sy No. 83/1 Plot No. 02, Raidurg Hyderabad – 500 081, India Telephone + 91 407 182 2000 Fax + 91 407 182 2399

Limited Review Report on unaudited consolidated financial results of NATCO Pharma Limited for the quarter ended 30 September 2024 and year to date results for the period from 01 April 2024 to 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

#### To the Board of Directors of NATCO Pharma Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of NATCO Pharma Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2024 and year to date results for the period from 01 April 2024 to 30 September 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Name of the entity	Relationship
NATCO Pharma Limited	Parent
NATCO Pharma Inc., United States of America ('USA')	Subsidiary
NATCO Pharma USA LLC, USA (Formerly known as Dash Pharmaceuticals LLC, USA - name changed w.e.f. 12 April 2023) (Subsidiary of NATCO Pharma Inc.)	Step-down Subsidiary
Time Cap Overseas Limited, Mauritius ('TCOL')	Subsidiary

4. The Statement includes the results of the following entities :

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center Western Express Highway, Goregaon (East), Mumbar - 400063

Page 1 of 3

# Limited Review Report (Continued) NATCO Pharma Limited

NatcoFarma do Brasil Ltda., Brazil (Subsidiary of TCOL)	Step-down Subsidiary
NATCO Pharma (Canada) Inc., Canada	Subsidiary
NATCO Pharma Asia Pte. Ltd., Singapore	Subsidiary
NATCO Pharma Australia PTY Ltd., Australia	Subsidiary
NATCO Lifesciences Philippines Inc., Philippines	Subsidiary
NATCO Pharma UK Limited, United Kingdom	Subsidiary
PT. NATCO Lotus Farma, Indonesia	Subsidiary
NATCO Pharma Colombia S.A.S.	Subsidiary

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial information of ten subsidiaries/ step down subsidiaries included in the Statement, whose interim financial information reflect total assets (before consolidation adjustments) of INR 9,699 million as at 30 September 2024 and total revenues (before consolidation adjustments) of INR 1,077 million and INR 2,791 million, total net profit after tax (before consolidation adjustments) of INR 159 million and INR 465 million and total comprehensive income (before consolidation adjustments) of INR 159 million and INR 465 million for the quarter ended 30 September 2024 and for the period from 01 April 2024 to 30 September 2024 respectively, and cash inflows (net) (before consolidation adjustments) of INR 341 million for the period from 01 April 2024 to 30 September 2024. as considered in the Statement. These interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

These subsidiaries/ step down subsidiaries are located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries/ step down subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in their respective conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries/ step down subsidiaries located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Parent and reviewed by us.

Page 2 of 3

## Limited Review Report (Continued)

## **NATCO Pharma Limited**

7. The Statement includes the interim financial information of one subsidiary which has not been reviewed, whose interim financial information reflects total assets (before consolidation adjustments) of INR Nil as at 30 September 2024 and total revenues (before consolidation adjustments) of INR Nil and INR Nil, total net profit after tax (before consolidation adjustments) of INR Nil and INR Nil and INR Nil and total comprehensive income (before consolidation adjustments) of INR Nil and INR Nil and INR Nil and for the period from 01 April 2024 to 30 September 2024 respectively, and cash flows (net) (before consolidation adjustments) of INR Nil for the period from 01 April 2024 to 30 September 2024 as considered in the Statement. According to the information and explanations given to us by the Parent's management, this interim financial information is not material to the Group

Our conclusion is not modified in respect of this matter.

For BSR and Co

Chartered Accountants Firm's Registration No.:128510W

NAC

Amit Kumar Bajaj Partner Membership No.: 218685 UDIN:24218685BKGPQF7711

Hyderabad 12 November 2024



Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034

Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

### STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30-09-2024

S.No.	Particulars		Quarter ended		Half yea	r ended	Year ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from operations	12,926	12,369	9,305	25,295	19,788	35,689
2	Other income	514	398	247	912	393	1,047
3	Total income (1+2)	13,440	12,767	9,552	26,207	20,181	36,736
4	Expenses						
	Cost of materials consumed	1,432	1,513	1,666	2,945	3,027	5,225
	Purchases of stock-in-trade	133	77	68	210	157	348
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7)	(134)	75	(141)	395	172
	Employee benefits expense	1,328	1,202	1,068	2,530	2,260	4,549
	Finance costs	30	44	30	74	62	145
	Depreciation and amortisation expense	422	404	400	826	799	1,719
	Other expenses	2,133	2,081	2,005	4,214	4,489	9,025
	Total expenses	5,471	5,187	5,312	10,658	11,189	21,183
5	Profit before tax for the period/ year (3-4)	7,969	7,580	4,240	15,549	8,992	15,553
6	Tax expense						
	(i) Current tax	1,478	1,324	753	2,802	1,591	2,848
	(ii) Deferred tax	(120)	(107)	(115)	(227)	(254)	(361
	Total tax expense	1,358	1,217	638	2,575	1,337	2,487
7	Profit for the period/ year (5-6)	6,611	6,363	3,602	12,974	7,655	13,066
8	Other comprehensive income/ (loss) (net of tax)						
	Items that will not be reclassified to profit or loss:						
	Remeasurement of defined benefit liability/(asset)	-	-	-	-	-	(20
	Tax on remeasurement of defined benefit liability/(asset)	-	-	-	-	-	7
	Fair value changes in Equity investments through OCI	50	26	25	76	76	97
	Tax impact of Fair value changes in Equity investments through OCI	(7)	(4)	(3)	(11)	(7)	(8
	Other comprehensive income/ (loss) for the period/ year, net of tax	43	22	22	65	69	76
9	Total comprehensive income for the period/ year (7+8)	6,654	6,385	3,624	13,039	7,724	13,142
10	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358	358	358
11	Other equity	000	000	000	000	000	55,565
							55,505
12	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)						
	Basic (in ₹)	36.91	35.53	20.11	72.44	42.56	72.79
	Diluted (in ₹)	36.91	35.53	20.11	72.44	42.56	72.79

See accompanying notes to the unaudited standalone financial results.

Continued..



tandalone Balance Sheet:		(₹ in millio
	As at	As at
	30-09-2024 (Unaudited)	31-03-2024 (Audited)
Assets	,	
1) Non-current assets		
(a) Property, plant and equipment	22,799	22,7
(b) Capital work-in-progress	2,303	1,3
(c) Other intangible assets	801	1
(d) Investment in subsidiaries	4,895	4,8
(e) Financial assets		
(i) Investments	961	ç
(ii) Loans	5	
(iii) Other financial assets	1,987	4
(f) Deferred tax assets, net	286	
(g) Non-current tax assets, net	24	2
(h) Other non-current assets	584	6
Total non-current assets	34,645	31,4
(a) Inventories	0.040	
(b) Financial assets	6,640	5,9
(i) Investments	0.000	10
	2,223	1,6
(ii) Trade receivables	13,164	10,7
(iii) Cash and cash equivalents	55	
(iv) Bank balances other than (iii) above	14,197	8,5
(v) Loans	101	
(vi) Other financial assets	4,195	4,4
(c) Other current assets	2,890	2,5
Total current assets	43,465	34,1
Total assets	78,110	65,5
EQUITY AND LIABILITIES		
1) Equity		
(a) Equity share capital	358	3
(b) Other equity	68,067	55,5
Total equity	68,425	55,9
i otal equity	00,423	
2) Liabilities		
(A) Non-current liabilities		
(a) Financial liabilities		
(ia) Lease liabilities	12	
(ii) Other financial liabilities	44	
(b) Provisions	695	7
Total non-current liabilities	751	7
(B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	2,010	3,6
(ia) Lease liabilities	10	
(ii) Trade payables		
-Total outstanding dues of micro enterprises and small enterprises; and	96	
-Total outstanding dues of creditors other than micro enterprises		
and small enterprises	2,272	1,7
(iii) Other financial liabilities	1,011	ç
(b) Other current liabilities	1,491	1,0
(c) Provisions	870	1,0
(d) Current tax liabilities (net)	1,174	
Total current liabilities	8,934	8,8
Total liabilities	9,685	9,6
Total equity and liabilities	78,110	65,5
		00,0



## Standalone Statement of Cash Flows:

(₹ in millions)

The Dispersion Law Services         15,549         8,59           Depreciation and amortisation expense         826         77           Depreciation and amortisation expense         826         78           Depreciation and amortisation expense         826         78           Depreciation and amortisation expense         683         030           Depreciation and amortisation expense         683         030           Statustion income         -         44           Statustion income         -         44           Statustion income         -         -           Vision of impairment of receivables and advances, net         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease in the frameworking capital devisions         -         -           Decrease in the receivables         -         -         -           Decrease in the framed liabilities         -         -         -           Decrease in the framed liabilities         -         -         -           Decrease in the framed liabilities	Standalone Statement of Cash Flows:		(₹ in millions)
Image         (manufact)         (manufact)           2ah flows from operating activities         15,549         8,59           Adjustments for appreciation and amotisation expense         628         78           preciation and amotisation expense         628         630           statistics         74         6           transmission expense         631         630           statistics         73         62           statistics         73         62           statistics         73         62           statistics         63         620           Statistics         63         621           Statistics         63         621           Statistics         63         621           Statistics         63         623           Statistics         63         63           Statistics         63         73           Statistics         640         63           Statistics         640         63 <th></th> <th>Half yea</th> <th>ar ended</th>		Half yea	ar ended
Stah flows from operating activities     15.540     8.39       Forth before tax for the period     15.540     8.39       Depreciation and amotisation expense     8.66     74       Instance costs     6.63     73       Depreciation and amotisation expense     6.63     (63)       Instance costs     6.63     (63)       Stat debts written off     -     4       Deresting portful forfor working capital changes     -     15,777       Deressel in roome capital inscription     (671)     4       Increase in trade receivables     (2,370)     (2,474)       Increase in trade receivables     (2,376)     7,35       Decresse) increase in name capital activities     (2,376)     7,35       Decresse) increase in after on operating activities     (2,176)     7,05       Stat debts written on operating activities     (1,174)     (1,174)       Varches of property, plant and equipment     (2,176)     7,05       Varches of property, plant and equipment     (2,176)     7,05       Varches of property, plant and equipment     (1,174)     (1,174)		30-09-2024	
The Dispersion Law Services         15,549         8,59           Depreciation and amortisation expense         826         77           Depreciation and amortisation expense         826         78           Depreciation and amortisation expense         826         78           Depreciation and amortisation expense         683         030           Depreciation and amortisation expense         683         030           Statustion income         -         44           Statustion income         -         44           Statustion income         -         -           Vision of impairment of receivables and advances, net         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease in the frameworking capital devisions         -         -           Decrease in the receivables         -         -         -           Decrease in the framed liabilities         -         -         -           Decrease in the framed liabilities         -         -         -           Decrease in the framed liabilities		(unaudited)	(unaudited)
The Dispersion Law Services         15,549         8,59           Depreciation and amortisation expense         826         77           Depreciation and amortisation expense         826         78           Depreciation and amortisation expense         826         78           Depreciation and amortisation expense         683         030           Depreciation and amortisation expense         683         030           Statustion income         -         44           Statustion income         -         44           Statustion income         -         -           Vision of impairment of receivables and advances, net         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease of intersent mark and explorement         -         -           Devision of mease in the frameworking capital devisions         -         -           Decrease in the receivables         -         -         -           Decrease in the framed liabilities         -         -         -           Decrease in the framed liabilities         -         -         -           Decrease in the framed liabilities	Cash flows from operating activities		
Depreseition and amortisation expense         822         74           Interact income         (683)         (63)           Provision for impairment of receivables and advances, net         -<	Profit before tax for the period	15,549	8,992
Depreseition and amortisation expense         822         74           Interact income         (683)         (63)           Provision for impairment of receivables and advances, net         -<	Adjustments for		
inance costs         74         6           Provision for impairment of receivables and advances, net         - <t< td=""><td></td><td>826</td><td>799</td></t<>		826	799
Trovision for impairment of receivables and advances, net.         -	Finance costs	74	62
Trovision for impairment of receivables and advances, net.         -	Interest income	(683)	(309)
vel. Loss? (gain) on sale of property, plant and equipment     35     (2       Jurrantes for loss?     (7)     (1)       Jurrantes for loss?     (7)     (2)       Jurrantes for loss?     (7)     (1)       Jurrantes for loss?     (7)     (1)       Jurrantes for loss?     (1)     (1)       Jurrantes for loss?	Provision for impairment of receivables and advances, net	-	48
vel. Loss? (gain) on sale of property, plant and equipment     35     (2       Jurrantes for loss?     (7)     (1)       Jurrantes for loss?     (7)     (2)       Jurrantes for loss?     (7)     (1)       Jurrantes for loss?     (7)     (1)       Jurrantes for loss?     (1)     (1)       Jurrantes for loss?	Bad debts written off	-	42
Profit/ loss on sale of investments (5) (1) Divided income on equivivestment at fair value through other comprehensive income (2) (2) (2) Paralised foreign exchange loss/gain), net (17) (1) Parages in working capital changes (2) (2) (2) (2) Parages in working capital changes (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)	Net Loss/ (gain) on sale of property, plant and equipment	35	(29
Juaranties income       -       -       (1)         Juranties foreign exchange loss/(gain), net       -       (17)       (1)         Derating porticing control before working capital changes       -       (2)       (2)         Increase in trade receivables       (2379)       (2.471)       4.84         Increase in trade receivables       (233)       (57         Increase in other assets       (233)       (57         Decrease) in trade receivables       (39)       1         Increase in other assets       (39)       1         Decrease) in trade receivables       (39)       1         Increase in other inancial labilities       (39)       1         Decrease in other inancial labilities       (39)       1         Decrease in other inancial labilities       (39)       1         Decrease in other inancial labilities       (49)       (87)         Cash flows from operating activities (A)       10.987       6.05         Decrease in other inancial labilities       (76)       (24)         Tyrobeed from sale of property, plant and equipment       (1,764)       (1,774)         Tyrobeed from sale of property, plant and equipment       (77)       (6)         Tyrobeed from sale of property, plant and equipment       (76)<	(Profit)/ loss on sale of investments	(5)	11
Divided income on equivitives         (2)         (3)           Deratised foreign exchange loss/gain), net         (17)         (1           Derating profit before working capital changes         (3)         (5,77)         9,60           Increase) in order receivables         (2,37)         (2,47)         (4)           Increase in other financial assets         (2,37)         (2,47)         (4)           Increase in other financial assets         (2,33)         (6,7)         (4)           Decrease) in other financial labilities         (3)         (1,7)         (4)           Decrease) in other financial labilities         (3)         (1,7)         (4)           Decrease) in other financial labilities         (3)         (1,7)         (1,7)           Decrease) in other financial labilities         (3)         (1,7)         (1,7)           Decrease) in other financial labilities         (3)         (1,7)         (1,7)           Decrease in other financial labilities         (3)         (1,7)         (1,7)           Decrease in other financial labilities         (2,7)         (7,5)         (7,5)           Cash flows from investing activities (A)         (1,7)         (1,7)         (1,7)           Orcocods from asie of investing activities (A)         (2,6) <td< td=""><td>Guarantee income</td><td>-</td><td>(1</td></td<>	Guarantee income	-	(1
Interested foreign exchange loss/(gain), net     (17)     (1       Departing porfix before working capital changes     (5,777)     9,60       Increase in trade receivables     (6,71)     (4       Increase in trade receivables     (2,378)     (2,477)       Increase in other assets     (233)     (57       necrease in other assets     (233)     (57       Decrease/increase in other inancial assets     (38)     14       Decrease/increase in other financial labilities     (39)     14       Decrease/increase in other financial labilities     (39)     14       Decrease/increase in other financial labilities     (49)     (67       2ach generated from operating activities (A)     10,987     6.655       2ach flows from investing activities (A)     11,764     (1,47       2ach flows for sale of	Dividend income on equity investment at fair value through other comprehensive income	(2)	(2
Derating profit before working capital changes       15,777       9,60         Darages in working capital       (671)       48         Increase) in prote receivables       (2,370)       (2,477)         Increase) in trade payables       555       77         Decrease) in rords en in other financial assets       (2)       (3)       (77)         Decrease) in rords en in other financial labilities       (2)       (3)       (1)       48         Decrease) in rords payables       555       77       70       (3)       (4)       (2)       (4)       (4)       (2)       (7)       (4)       (1)       (4)       (7) </td <td></td> <td></td> <td>(11</td>			(11
Changes in working capital       (671)       48         Increase in trade receivables       (2,379)       (2,47         Increase in trade receivables       (2,379)       (2,47         Increase in inder receivables       (283)       (57         Increase in inder receivables       (293)       (57         Decrease) increase in other financial liabilities       (293)       (173)         Decrease) increase in other financial liabilities       (244)       (67         Decrease indication of the intrancial liabilities       (171)       (44)         Decrease indication of intrancial activities       (171)       (14)         Cash generated from operating activities       (171)       (171)         Unchase of property, plant and equipment       (170)       (171)         Varchase of property, plant and equipment       (170)       (171)         Varchase of property, plant and equipment       (171)       (171)         Varchase of property, plant and equipment       (172)       (171)         Varchase of property, plant and equipment       (173)       (174)         Varchase of property, plant and equipment       (176)       (173)         Varchase of property, plant and equipment       (178)       (173)         Varchase of property, plant and equipment       <			9,602
Increase)     (671)     48       Increase)     (2,37)     (2,47)       Increase)     (2,39)     (2,47)       Increase)     (2,39)     (2,47)       Increase)     (2,37)     (2,47)       Increase)     (3)     (7)       Decrease)     (1,70)     14       Decrease)     (1,77)     14       Decrease)     (1,76)     (1,70)       Vet tash generated from operating activities (A)     10,987     6.00       Cash flows from investing activities (A)     (1,76)     (1,76)       Proceeds from sale of propery, plant and equipment     (1,76)     (1,76)       Proceeds from sale of investments     (1,76)     (1,76)       Proceeds from sale of investments     (1,76)     (1,76)       Proceeds from sale of investments     (1,76)     (1,26)       Proceeds from sale of investmen		,	
ncrease in trade receivables (2.379) (2.47 ncrease) increases in other inancial assets (2.379) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379) (3.372) (3.379)	(Increase)/ decrease in inventories	(671)	485
Increase) decrease in other financial assets ncrease in prare assets (293) (3) ncrease in prare assets (293) (37 ncrease in prare assets (293) (37 ncrease in prare assets (293) (37 ncrease in prare assets (39) (173) (173) (173) (173) (174) (234) Decrease) increase in other financial liabilities (39) (177) (12,705 (17	Increase in trade receivables		(2,473
ncrease in tother assets ncrease in tother assets ncrease in tother financial liabilities Decrease ly increase in other financial liabilities Decrease ly increase increase in the other than with banks Decrease ly increase increase increase in the other banks Decrease ly increase in other financial liabilities (refer note below) Dividend paid Dividend recease in financing activities (C) Decrease ly increase in accordance with lind AS 7: Decrease liabilities in accordance with lind AS 7: Decrease liabilities in accordance with lind AS 7: Decrease liabilities (refer note below) Dividend Sp adi Decrease liabilities in accordance with lind AS 7: Decrease liabilities (refer note below) Dividend Sp adi Decrease liabilities in accordance with lind AS 7: Decrease liabilities (refer note below) Di	(Increase)/ decrease in other financial assets		6
ncrease in trade payables 535 73 Decrease) increase in provisions (173) 14 Decrease) increase in other financial liabilities (4) Decrease in other liabilities (4) Decrease in cher liabilities (4) Decrease of property, plant and equipment (1,716) (1,776) Type of the cher o	Increase in other assets		(577
Decrease)/ increase in other financial liabilities Decrease in other financial liabilities Cash generated from operating activities Cash flows from investing activities Cash flows from investing activities Cash flows from investing activities Cash flows form investing activities Cash flows from financing activities Cash flows flow flows flow flows flow flow flow flow flow flow flow flow	Increase in trade payables		731
Decrease in other liabilities       (49)       (47)         Cash generated from operating activities (A)       12,705       7,05         Cash denerated from operating activities (A)       10,987       6,055         Cash flows from investing activities (A)       11,748       (1,748)         Varchase of property, plant and equipment       (1,748)       (707)       (1         Avarance for sale of property, plant and equipment       (76)       (34         Avarance for sale of investments       (1,748)       (11)       1         Proceeds from sale of investments       (1,748)       (10,835)       (5,233)         Varchase of investments       (1,768)       (18)       (10,835)       (5,232)         Scash flows from financing activities (B)       (2,927)       (3,09)       (2,288)       (2,297)       (3,09)         Vet cash used in investing activities (B)       (2,243)       (3,06)       (1,224)       (72)       (6)         Cash flows from financing activities (C)       (2,243)       (3,06)       (2,233)       (3,05)       (	(Decrease)/ increase in provisions	(173)	142
2ash generated from operating activities       12,705       7,05         ncome-taxes paid, net of refund       (1,718)       (1,000         Vet cash generated from operating activities (A)       10,987       6,05         Cash flows from investing activities       (1,718)       (1,001         Varchase of property, plant and equipment       2       5         Vaccedis from sale of property, plant and equipment       2       5         Varchase of investments in subsidiaries       (767)       (1         Repayment of loans by others       (11)       1         Proceeds from sale of investments       1,340       1,02         Proceeds from sale of property, plant and equipment       2       5         Varchase of investments       (1,776)       (1         Proceeds from sale of investments       1,340       1,02         Varchase of investments       (1,786)       (18         Payment of busk deposits       5,231       3,21         Therest received       600       42         Dividend received       8       2         Stah flows from financing activities (B)       (2,227)       (3,09         Vet cash used in investing activities (C)       (2,23)       (3,06         Vet cash used in financing activities (C)       <	(Decrease)/ increase in other financial liabilities	(39)	16
ncome-taxes paid, net of refund (1,718) (1,00 10,987 6,05 2ahs flows from investing activities (A) 2ahs flows from investing activities (A) 2ahs flows from investing activities Purchase of property, plant and equipment 4(1,704) (1	Decrease in other liabilities	(49)	(874
ncome-taxes paid, net of refund (1,718) (1,00 10,987 6,05 2ahs flows from investing activities (A) 2ahs flows from investing activities (A) 2ahs flows from investing activities Purchase of property, plant and equipment 4(1,704) (1	Cash generated from operating activities	12,705	7,058
Cash flows from investing activities       (1,704)       (1,774)         Purchase of property, plant and equipment       2       5         Varance for sale of property, plant and equipment       501       501         Varance for sale of property, plant and equipment       501       501         Varance for sale of property, plant and equipment       501       501         Varance for sale of investments       (1707)       (1         Varchase of investments       (1,104)       1,340       1,02         Proceeds from sale of investments       (1,174)       (1,174)       1,340       1,02         Varchase of investments       (1,174)       (1,174)       1,340       1,02         Payrchase of investments       (1,174)       (1,174)       1,400       1,02         Varchase of investments       (1,174)       (1,174)       1,120	Income-taxes paid, net of refund	(1,718)	(1,006
Purchase of property, plant and equipment       (1,704)       (1,47)         Proceeds from sale of property, plant and equipment       2       5         Avance for sale of property, plant and equipment       501       (707)       (         Vextame for sale of property, plant and equipment       (11)       1<	Net cash generated from operating activities (A)	10,987	6,052
Purchase of property, plant and equipment       (1,704)       (1,47)         Proceeds from sale of property, plant and equipment       2       5         Avance for sale of property, plant and equipment       501       (707)       (         Vextame for sale of property, plant and equipment       (11)       1<	Cash flows from investing activities		
Proceeds from sale of property, plant and equipment     2     5       Advance for sale of property, plant and equipment     501     501       Advance for sale of property, plant and equipment     501     501       Advance for sale of property, plant and equipment     501     501       Advance for sale of property, plant and equipment     501     501       Advance for sale of property, plant and equipment     501     501       Advance for sale of property, plant and equipment     600     600       Parchage of investments     5231     3,21       Parcededs from sale of investments     5231     3,21       Parceedevid     600     42       Parceevide     2     2       Redemption of bank deposits other than with banks     1,626     2,62       Parceived     2     2       Parceevide     2     2       Parceevide     2     2       Redemption of deposits other than with banks     1,626     2,62       Parceived     2     2     2       Parceaver     2     2     2       Redemption of poposits other than with banks     1,626     2,62       Vet cash used in investing activities (B)     (2,927)     (3,09       Cash flows from financing activities (C)     (2,53     (1,624)		(1 704)	(1.476
Advance for sale of property, plant and equipment     501       Acquisition of intangible assets     (707)       Acquisition of intangible assets     (707)       Neestments in subsidiaries     (711)       Proceeds from sale of investments     1,340       Purchase of investments     (1,786)       Purchase of investments     (1,786)       Proceeds from sale of investments     (1,786)       Proceeds from sale of investments     (1,786)       Proceeds from sale of investments     (1,786)       Payment of bank deposits     (1,786)       Interest received     600       Addemption of deposits other than with banks     (2,927)       Sedemption of deposits other than with banks     (2,927)       Scash flows from financing activities (B)     (1,624)       Cash flows from financing activities     (1,286)       Payment of hybrack of shares, including transaction costs and taxes on buy-back     -       Vet (repayment of) proceeds short-term borrowings (refer note below)     (1,624)       Net cash used in financing activities (C)     (2,243)       Net cash used in financing activities (C)     (2,243)       Net increase/ (decrease) in cash and cash equivalents (A+B+C)     -       Cash and cash equivalents as at the end of the period     55       Cash and cash equivalents as at the end of the period     55 <t< td=""><td></td><td></td><td>52</td></t<>			52
Acquisition of intangible assets       (707)       (         nvestments in subsidiaries       (707)       (         Repayment of loans by others       (11)       1         Proceeds from sale of investments       1.340       1.02         Purchase of investments       (10,835)       (5,231)         Purchase of investments       5.231       3.21         Purchase of activities       600       42         Dividend received       600       42         Deposits with banks       1,626       2.62         Sedemption of deposits other than with banks       (2,927)       (3.09         Vet cash used in investing activities (B)       (8,744)       (2,987)         Cash flows from financing activities       (1,624)       79         Payment on buy-back of shares, including transaction costs and taxes on buy-back       -       (2,53         Vet cash used in financing activities (C)       (2,243)       (3.06         Net cash used in financing activities (C)       (2,243)       (3.06         Net increase/ (decrease) in cash and cash equivalents (A+B+C)       -       (2,243)         Cash and cash equivalents as at the beginning of the period       55       6         Cash and cash equivalents as at the end of the period       55       6			-
nvestments in subsidiaries       (76)       (34         Rapayment of loans by others       (11)       1         Proceeds from sale of investments       (1,786)       (18         Deposits with banks       (10,835)       (5,23)         Redemption of bank deposits       (10,835)       (5,23)         Interest received       (10,835)       (10,835)         Dividend received       (2       (2         Redemption of bank deposits other than with banks       (1,86)       (18         Deposits other than with banks       (2,927)       (3,09         Vet cash used in investing activities       (2,927)       (3,09         Reademption of proceeds short-term borrowings (refer note below)       (1,824)       79         Dividends paid       (72)       (6       (72)         Fincipal and interest payment of lease liabilities (refer note below)       (9)       (1,824)       79         Dividends paid       (72)       (6       (538)       (1,25       6         Cash and cash equivalents as at the beginning of the period       55       6       6         Net: increase/ (decrease) in cash and cash equivalents (A+B+C)       -       (1,624)       7         Cash and cash equivalents as at the end of the period       55       6 <t< td=""><td></td><td></td><td>(2</td></t<>			(2
Repayment of loans by others(11)1Proceeds from sale of investments1,3401,02Purchase of investments(1,786)(18Deposits with banks(10,835)(5,23Redemption of bank deposits5,2313,21Interest received60042Dividend received22Redemption of deposits other than with banks1,6262,62Deposits other than with banks(2,927)(3,00Vet cash used in investing activities(1,624)79Payment of // proceeds short-term borrowings (refer note below)(1,624)79Dividends paid(1,624)79(6,38)Dividends paid(2,243)(3,06(1,624)Principal and interest payment of lease liabilities (refer note below)(9)(Net cash used in financing activities (C)-(2,243)(3,06Net increase/ (decrease) in cash and cash equivalents (A+B+C)-((Cash and cash equivalents as at the end of the period5566Cash and cash equivalents as at the end of the period5566Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:2(Current borrowings(1,624)77(Qpening balance2,913,6321,5,8Quest itilities2,913,6321,5,8Quest itilities2,0102,382,383,6321,5,8Quest itilities2,91222<	Investments in subsidiaries		(347
Proceeds from sale of investments          Proceeds from sale of investments       1,340       1,02         Purchase of investments       (1,786)       (18         Deposits with banks       (10,835)       (5,231         Redemption of bank deposits       5,231       3,21         Interest received       600       42         Dividend received       2       2         Redemption of deposits other than with banks       1,626       2,62         Deposits with than with banks       1,626       2,62         Deposits other than with banks       1,626       2,62         Payment on buy-back of shares, including transaction costs and taxes on buy-back       -       (2,53)         Vet (repayment of)/ proceeds short-term borrowings (refer note below)       (1,624)       79         Dividends paid       (538)       (1,25)       (2,243)       (3,06)         Principal and interest payment of lease liabilities (refer note below)       (9)       (1,624)       79         Oriclash and cash equivalents as at the beginning of the period       55       6       6         Cash and cash equivalents as at the of of the period       55       6       6         Note: Movement in borrowings       3,632       1,52       1,52         Opening balance       2,010       <	Repayment of loans by others		13
Purchase of investments(1,786)(18Deposits with banks(10,635)(5,231Redemption of bank deposits5,2313,21Interest received22Redemption of deposits other than with banks1,6262,62Dividend received2(1,786)(18Redemption of deposits other than with banks1,6262,62Deposits other than with banks(2,927)(3.09Net cash used in investing activities(8,744)(2,987)Payment on buy-back of shares, including transaction costs and taxes on buy-back-(2,53Net (repayment of) proceeds short-term borrowings (refer note below)(1,624)79Dividends paid(538)(1,25(1,624)Finance cost paid(2,243)(3,06Principal and interest payment of lease liabilities (refer note below)(9)(16,24)Net increase/ (decrease) in cash and cash equivalents (A+B+C)-(2,243)Cash and cash equivalents as at the end of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:2(1,624)Current borrowings(1,624)72(2,927)Quenity balance3,6321,532,533,632(Repayment of)/ Net proceeds from short-term borrowings(1,624)72Non-cash items (Foreign exchange changes)2(2,922Cash flow changes2,9012,383,6321	Proceeds from sale of investments		1,022
Deposits with banks(10.835)(5,23Redemption of bank deposits5,2313,21interest received260042Dividend received22Redemption of deposits other than with banks1,6262,62Deposits other than with banks(2,927)(3,09Vet cash used in investing activities(2,927)(3,09Payment on buy-back of shares, including transaction costs and taxes on buy-back-(2,53Vet (repayment of)/ proceeds short-term borrowings (refer note below)(1,624)79Dividends paid(72)(6Finance cost paid(72)(6Principal and interest payment of lease liabilities (refer note below)(9)(1Vet cash used in financing activities (C)-(2,243)(3,066)Net increase/ (decrease) in cash and cash equivalents (A+B+C)-((Cash and cash equivalents as at the beginning of the period556(Current borrowings3,6321,51((Dening balance3,6321,51((Repayment of)/ Net proceeds from short-term borrowings2(12(Opening balance22(2(2Cash flaw changes2(122(22Opening balance222(222Cash changes(9)((2222Non-cash thanges(9)(2 <td< td=""><td>Purchase of investments</td><td></td><td></td></td<>	Purchase of investments		
Redemption of bank deposits       5,231       3,21         Interest received       600       42         Dividend received       2       2         Redemption of deposits other than with banks       1,626       2,62         Deposits other than with banks       (2,927)       (3,09         Net cash used in investing activities (B)       (8,744)       (2,988         Cash flows from financing activities       -       (2,53         Payment of)/ proceeds short-term borrowings (refer note below)       (1,624)       79         Dividend received       (538)       (1,254)       (72)         Cash and cash equivalents (activities (C)       (2,243)       (3,006)       (2,243)       (3,006)         Net increase/ (decrease) in cash and cash equivalents (A+B+C)       -       -       (2,243)       (3,006)         Cash and cash equivalents as at the end of the period       55       6       -       (2,243)       (3,006)         Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:       -       -       (2,243)       (3,006)         Cash and cash equivalents as at the end of the period       55       6       -       -       (2,010)       -       2,3632       1,55       -       -       -       -       -	Deposits with banks		(5,231
nterest received 600 42 2xidem dreceived 2 2xedemption of deposits other than with banks 2 2eposits other than with banks 2 2eposite than banks 2 2eposite than banks 2 2e			3,218
Dividend received2Redemption of deposits other than with banks1,626Oeposits other than with banks1,626Oeposits other than with banks2,927Suge cash used in investing activities3,09Payment on buy-back of shares, including transaction costs and taxes on buy-back-Cash flows from financing activities-Payment of) / proceeds short-term borrowings (refer note below)(1,624)Dividends paid(538)Finance cost paid(72)Oricle and interest payment of lease liabilities (refer note below)(9)Net increase/ (decrease) in cash and cash equivalents (A+B+C)-Cash and cash equivalents as at the beginning of the period55Cash and cash equivalents as at the end of the period55Opening balance3,632(Repayment of)/ Net proceeds from short-term borrowings(1,624)Opening balance2(Cash libilities2Cash flow changes2Opening balance2Quast libilities2Cash flow changes2Opening balance2Quast libilities2Quast libilities2Opening balance29Quast libilities2Quast libilities2Quast libilities2Quast libilities2Quast libilities2Quast libilities2Quast libilities2Quast libilities2Quast libilities2Quast libilities2	Interest received		423
Deposits other than with banks       (2,927)       (3,09)         Net cash used in investing activities (B)       (8,744)       (2,98)         Cash flows from financing activities       (2,53)       (1,624)       79         Payment on buy-back of shares, including transaction costs and taxes on buy-back       (1,624)       79         Dividends paid       (538)       (1,25)       (1,253)         Principal and interest payment of lease liabilities (refer note below)       (9)       (1,624)       79         Net cash used in financing activities (C)       (2,243)       (3,06)       (2,243)       (3,06)         Net increase/ (decrease) in cash and cash equivalents (A+B+C)       (2,243)       (3,06)       (2,243)       (3,06)         Cash and cash equivalents as at the end of the period       55       6       (2,243)       (3,06)         Note: Movement in borrowings       and cash equivalents as at the end of the period       55       6       (1,624)       7         Non-cash items (Foreign exchange changes)       (1,624)       7       (1,624)       7       (1,624)       7         Lease liabilities       accordance with Ind AS 7:       2       (2       2       (1,624)       7         Qpening balance       (1,624)       7       2       (2       2 <td>Dividend received</td> <td></td> <td>2</td>	Dividend received		2
Deposits other than with banks       (2,927)       (3,09)         Net cash used in investing activities (B)       (8,744)       (2,98)         Cash flows from financing activities       (2,97)       (3,09)         Payment on buy-back of shares, including transaction costs and taxes on buy-back       -       (2,53)         Net (repayment of)/ proceeds short-term borrowings (refer note below)       (1,624)       79         Dividends paid       (538)       (1,25)         Finance cost paid       (72)       (6)         Principal and interest payment of lease liabilities (refer note below)       (9)       (1,624)       79         Net cash used in financing activities (C)       (2,243)       (3,06)       (2,243)       (3,06)         Net increase/ (decrease) in cash and cash equivalents (A+B+C)       -       (1,624)       (1,	Redemption of deposits other than with banks	1,626	2,627
Net cash used in investing activities (B)       (8,744)       (2,98         Cash flows from financing activities       -       (2,53         Payment on buy-back of shares, including transaction costs and taxes on buy-back       -       (2,53         Vet (repayment of)/ proceeds short-term borrowings (refer note below)       (1,624)       79         Dividends paid       (538)       (1,25         Finance cost paid       (72)       (6         Principal and interest payment of lease liabilities (refer note below)       (9)       (1         Net cash used in financing activities (C)       (2,243)       (3,060         Net increase/ (decrease) in cash and cash equivalents (A+B+C)       -       (6         Cash and cash equivalents as at the beginning of the period       55       6         Cash and cash equivalents as at the end of the period       55       6         Note: Movement in borrowings       (1,624)       75         Opening balance       3,632       1,55         (Repayment of)/ Net proceeds from short-term borrowings       (1,624)       75         Non-cash items (Foreign exchange changes)       2       (2         Lease liabilities       29       1         Opening balance       29       1         Cash flow changes       29       1	Deposits other than with banks		(3,098
Payment on buy-back of shares, including transaction costs and taxes on buy-back-(2,53)Net (repayment of)/ proceeds short-term borrowings (refer note below)(1,624)79Dividends paid(538)(1,25Finance cost paid(72)(6Principal and interest payment of lease liabilities (refer note below)(9)(Net cash used in financing activities (C)(2,243)(3,06Net increase/ (decrease) in cash and cash equivalents (A+B+C)-(Cash and cash equivalents as at the beginning of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings3,6321,57Opening balance3,6321,57(Repayment of)/ Net proceeds from short-term borrowings2(Non-cash items (Foreign exchange changes)2(Lease liabilities290Opening balance290Cash flow changes(9)(Non-cash changes22Cash chang	Net cash used in investing activities (B)		
Payment on buy-back of shares, including transaction costs and taxes on buy-back-(2,53)Net (repayment of)/ proceeds short-term borrowings (refer note below)(1,624)79Dividends paid(538)(1,25Finance cost paid(72)(6Principal and interest payment of lease liabilities (refer note below)(9)(Net cash used in financing activities (C)(2,243)(3,06Net increase/ (decrease) in cash and cash equivalents (A+B+C)-(Cash and cash equivalents as at the beginning of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings3,6321,57Opening balance3,6321,57(Repayment of)/ Net proceeds from short-term borrowings2(Non-cash items (Foreign exchange changes)2(Lease liabilities290Opening balance290Cash flow changes(9)(Non-cash changes22Cash chang			
Net (repayment of)/ proceeds short-term borrowings (refer note below)(1,624)79Dividends paid(538)(1,25Finance cost paid(72)(6Principal and interest payment of lease liabilities (refer note below)(9)(1,624)Net cash used in financing activities (C)(2,243)(3,06Net increase/ (decrease) in cash and cash equivalents (A+B+C)-(Cash and cash equivalents as at the beginning of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:-(Current borrowings Non-cash items (Foreign exchange changes)2(1,624)Lease liabilities Opening balance (Repayment of)/ Net proceeds from short-term borrowings Non-cash items (Foreign exchange changes)2(Lease liabilities Opening balance (Cash flow changes (Pening balance291Opening balance (Cash flow changes291Opening balance (Opening balance (Opening balance291Opening balance (Opening balance (Opening balance291Opening balance (Opening balance (Opening balance291Opening balance (Opening balance (Opening balance (Opening balance (Opening balance (	Cash flows from financing activities		
Dividends paid(538)(1,25)Finance cost paid(72)(6)Principal and interest payment of lease liabilities (refer note below)(9)(Net cash used in financing activities (C)(2,243)(3,06)Net increase/ (decrease) in cash and cash equivalents (A+B+C) Cash and cash equivalents as at the beginning of the period-(Cash and cash equivalents as at the beginning of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7: Current borrowings3,6321,55Chrent borrowings Opening balance (Repayment of)/ Net proceeds from short-term borrowings Non-cash items (Foreign exchange changes)2(Lease liabilities Opening balance Cash flow changes291Cash flow changes Non-cash changes291Current borrowings(9)(Cash flow changes Cash flow changes22		-	(2,537
Finance cost paid(72)(6Principal and interest payment of lease liabilities (refer note below)(9)(Net cash used in financing activities (C)(2,243)(3,06Net increase/ (decrease) in cash and cash equivalents (A+B+C)-(Cash and cash equivalents as at the beginning of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:-(Current borrowings3,6321,50Opening balance3,6321,50(Repayment of)/ Net proceeds from short-term borrowings2(Non-cash items (Foreign exchange changes)2(Lease liabilities291Opening balance291Cash flow changes(9)(Non-cash changes22Opening balance22Cash flow changes22Opening balance291Cash flow changes22Opening balance22Cash flow changes22Opening balance22Cash flow changes2		(1,624)	792
Principal and interest payment of lease liabilities (refer note below)       (9)         Net cash used in financing activities (C)       (2,243)         Net increase/ (decrease) in cash and cash equivalents (A+B+C)       -         Cash and cash equivalents as at the beginning of the period       55         Cash and cash equivalents as at the end of the period       55         Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:       -         Current borrowings       3,632       1,59         Opening balance       3,632       1,59         (Repayment of)/ Net proceeds from short-term borrowings       2       2         Lease liabilities       2,010       2,38         Opening balance       29       1         Cash flow changes       (9)       0	Dividends paid	(538)	(1,255
Net cash used in financing activities (C)(2,243)(3,06)Net increase/ (decrease) in cash and cash equivalents (A+B+C) Cash and cash equivalents as at the beginning of the period-(Cash and cash equivalents as at the end of the period556Cash and cash equivalents as at the end of the period556Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7: Current borrowings-(Current borrowings Opening balance (Repayment of)/ Net proceeds from short-term borrowings Non-cash items (Foreign exchange changes)2(Lease liabilities Opening balance Cash flow changes291Opening balance Cash flow changes22Opening balance Cash flow changes22Opening balance Cash flow changes22Opening balance Cash flow change	Finance cost paid		(60
Net increase/ (decrease) in cash and cash equivalents (A+B+C)       -       (         Cash and cash equivalents as at the beginning of the period       55       6         Cash and cash equivalents as at the end of the period       55       6         Cash and cash equivalents as at the end of the period       55       6         Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:       -       (         Current borrowings       3,632       1,55         Opening balance       3,632       1,55         (Repayment of)/ Net proceeds from short-term borrowings       (       1,624)       7         Non-cash items (Foreign exchange changes)       2       (       2       2         Lease liabilities       29       1       1       2       2       2         Non-cash flow changes       (9)       (       2       2       2       2       2	Principal and interest payment of lease liabilities (refer note below)		
Cash and cash equivalents as at the beginning of the period5566Cash and cash equivalents as at the end of the period5566Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:3,6321,55Current borrowings3,6321,556Opening balance3,6321,557(Repayment of)/ Net proceeds from short-term borrowings(1,624)7Non-cash items (Foreign exchange changes)2(1Lease liabilities291Opening balance291Cash flow changes(9)(1Non-cash changes22	Net cash used in financing activities (C)	(2,243)	(3,068
Cash and cash equivalents as at the beginning of the period5566Cash and cash equivalents as at the end of the period5566Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:3,6321,55Current borrowings3,6321,556Opening balance3,6321,557(Repayment of)/ Net proceeds from short-term borrowings(1,624)7Non-cash items (Foreign exchange changes)2(1Lease liabilities291Opening balance291Cash flow changes(9)(1Non-cash changes22	Net increase/ (decrease) in cash and cash equivalents ( $\Delta$ +R+C)	-	(1
Cash and cash equivalents as at the end of the period55Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:Current borrowingsOpening balance(Repayment of)/ Net proceeds from short-term borrowingsNon-cash items (Foreign exchange changes)Lease liabilitiesOpening balanceCash flow changes(9)(1)(1)(1)(2)(2)(2)(3)(4)<		55	69
Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:       Image: Current borrowings         Current borrowings       3,632       1,50         Opening balance       3,632       1,50         (Repayment of)/ Net proceeds from short-term borrowings       (1,624)       75         Non-cash items (Foreign exchange changes)       2       (1         Lease liabilities       2,010       2,38         Opening balance       29       1         Cash flow changes       (9)       (1         Non-cash changes       2       2			68
Current borrowings3,6321,53Opening balance3,6321,53(Repayment of)/ Net proceeds from short-term borrowings(1,624)7Non-cash items (Foreign exchange changes)2(1Lease liabilities2(1Opening balance291Cash flow changes(9)(1Non-cash changes22			
Opening balance3,6321,50(Repayment of)/ Net proceeds from short-term borrowings(1,624)70Non-cash items (Foreign exchange changes)2(1Lease liabilities2(1Opening balance291Cash flow changes(9)(1Non-cash changes22			
(Repayment of)/ Net proceeds from short-term borrowings(1,624)7Non-cash items (Foreign exchange changes)2(Lease liabilities2(Opening balance291Cash flow changes(9)(Non-cash changes22		3 632	1,59
Non-cash items (Foreign exchange changes)     2       Lease liabilities     2,010       Opening balance     29       Cash flow changes     (9)       Non-cash changes     2			
Lease liabilities2,0102,38Opening balance291Cash flow changes(9)(Non-cash changes22		(1,024)	(3
Lease liabilities29Opening balance29Cash flow changes(9)Non-cash changes2		2,010	2,388
Cash flow changes (9) ( Non-cash changes 2 2	Lease liabilities	_,	
Cash flow changes (9) ( Non-cash changes 2 2	Opening balance		
Non-cash changes 2 2	Cash flow changes	(9)	
	Non-cash changes		
		22	32

s 4



0



#### Notes to the unaudited standalone financial results:

- The unaudited standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited standalone financial results for the quarter and half year ended 30-09-2024 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 12-11-2024.
- 3) The unaudited standalone financial results of the Company for the quarter and half year ended 30-09-2024, have been reviewed by the statutory auditors and they have issued an unmodified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the unaudited consolidated financial results.
- 5) The Board of Directors at their meeting held on 12-11-2024 have approved an interim dividend of ₹ 1.5/- per equity share of ₹ 2 each for the quarter ended 30-09-2024 and at their meeting held on 12-08-2024 had approved interim dividend of ₹ 3/- per equity share of ₹ 2 each for the quarter ended 30-06-2024.

By order of the Board For NATCO Pharma Limited

V C Nannapaneni Chairman & Managing Director (DIN: 00183315)

Place: Hyderabad Date: 12 November 2024